Abstract
Background: Glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP) play a similar but complementary role in the regulation of glucose levels in islet β-cells. This study was aimed to develop a fusion peptide, which combines 4 tandem repeated GLP-1 and 4 tandem repeated GIP (4rolGG), and to investigate its therapeutic effect on type 2 diabetes using a diabetic mice model.
Methods: A 4rolGG expression plasmid was constructed and expressed in BL21 (DE3). By inducting with IPTG, 4rolGG was expressed at a high level, which was confirmed by SDS-PAGE electrophoresis and Western Blotting. Subsequently, 4rolGG was purified by Ni-NTA affinity chromatography and the purity of 4rolGG was up to 90%.
Result and Conclusion: After oral administration of 4rolGG for 4 weeks, streptozotocin-induced diabetic mice showed a dramatic reduction in the levels of plasma glucose, GHbA1C, TC and TG, while the insulin levels were increased significantly.
Keywords: GLP-1, GIP, diabetes, expression, purification, primers.
Graphical Abstract
Current Pharmaceutical Biotechnology
Title:Characterization of Optimized Functional-Complementary Dual Insulinotorpic Peptide rolGG
Volume: 18 Issue: 10
Author(s): Yaofang Zhang, Li Du, Yanling Xu, Lin Tian, Peipei Tu*Minggang Li*
Affiliation:
- Biological Engineering Department, College of Life Science, Anhui Medical University, 230032 Hefei, Anhui,China
- State Key Laboratory of Medicinal Chemical Biology, College of Life Science, Nankai University, 300071 Tianjin,China
Keywords: GLP-1, GIP, diabetes, expression, purification, primers.
Abstract: Background: Glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP) play a similar but complementary role in the regulation of glucose levels in islet β-cells. This study was aimed to develop a fusion peptide, which combines 4 tandem repeated GLP-1 and 4 tandem repeated GIP (4rolGG), and to investigate its therapeutic effect on type 2 diabetes using a diabetic mice model.
Methods: A 4rolGG expression plasmid was constructed and expressed in BL21 (DE3). By inducting with IPTG, 4rolGG was expressed at a high level, which was confirmed by SDS-PAGE electrophoresis and Western Blotting. Subsequently, 4rolGG was purified by Ni-NTA affinity chromatography and the purity of 4rolGG was up to 90%.
Result and Conclusion: After oral administration of 4rolGG for 4 weeks, streptozotocin-induced diabetic mice showed a dramatic reduction in the levels of plasma glucose, GHbA1C, TC and TG, while the insulin levels were increased significantly.
Export Options
About this article
Cite this article as:
Zhang Yaofang, Du Li , Xu Yanling, Tian Lin , Tu Peipei*, Li Minggang*, Characterization of Optimized Functional-Complementary Dual Insulinotorpic Peptide rolGG, Current Pharmaceutical Biotechnology 2017; 18 (10) . https://dx.doi.org/10.2174/1389201019666171204111908
DOI https://dx.doi.org/10.2174/1389201019666171204111908 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Is Impaired Flow-Mediated Dilatation of the Brachial Artery a Cardiovascular Risk Factor?
Current Vascular Pharmacology Pathogenesis of the Podocytopathy and Proteinuria in Diabetic Glomerulopathy
Current Diabetes Reviews Orofacial Pain and Mastication in Dementia
Current Alzheimer Research Epigenetic control of cardiovascular health by nutritional polyphenols involves multiple chromatin-modifying writer-reader-eraser proteins
Current Topics in Medicinal Chemistry Pancreatic Islet Transplantation in Type 1 Diabetes Mellitus: An Update on Recent Developments
Current Diabetes Reviews Modulatory Factors Responsible for Neoangiogenesis in Young Patients with Long-Standing Diabetes Mellitus Type 1
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Mineralocorticoid Receptor Antagonists in Primary Aldosteronism
Current Pharmaceutical Design Management of Adverse Effects from Atypical Antipsychotics
Current Psychopharmacology Innovative Models for the Empowerment of Patients with Type 2 Diabetes: The CAIPaDi Program
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Patent Selections:
Current Biomarkers (Discontinued) Small Artery Remodeling in Obesity and Insulin Resistance
Current Vascular Pharmacology The Application of Mass Spectrometry to Proteomics and Metabolomics in Biomarker Discovery and Drug Development
Current Molecular Pharmacology Cardiovascular Disease in Diabetes
Mini-Reviews in Medicinal Chemistry Patent Selections
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Mechanisms of Vascular Calcification and Associated Diseases
Current Pharmaceutical Design Abnormal Peri-Organ or Intra-organ Fat (APIFat) Deposition: An Underestimated Predictor of Vascular Risk?
Current Vascular Pharmacology Patient’s Perceptions of the Cannabis-psychosis Link - A Systematic Review
Current Pharmaceutical Design Highlights on Important Medicinal Plants for the Menopause Syndrome
Current Women`s Health Reviews Ageing as a Trait de Union Between Diabetes and Dementia for Frailty
CNS & Neurological Disorders - Drug Targets Formulation and Characterization of Gliclazide Oral Dissolving Films
Drug Delivery Letters